Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAD-1229 + Insulin in Type 2 Diabetes
NCT02154347Phase 4Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing KAD-1229/KAD-1229 with Placebo/KAD-1229 (2 arms). Primary endpoint: Change From Baseline in HbA1c at 16 weeks. Status: completed.
02
Drugs
mitiglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02154347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02154347.